MYCN and ependymoma: Based on the updated 2021 Central Nervous System WHO Classification, a novel subtype has been added because of a distinctive molecular trait, the presence of MYCN amplification, and an unfavorable outcome.[18]MYCN amplification in ependymomas demonstrates aggressive biological behaviors, including early metastasis, rapid progression after recurrence, and dissemination and metastasis within the central nervous system.